Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berzosertib - Merck KGaA

Drug Profile

Berzosertib - Merck KGaA

Alternative Names: Captisol® enabled VX 970; M-6620; MSC 2527093A; VX-970

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EMD Serono Research & Development Institute; Massachusetts General Hospital; Merck KGaA; National Cancer Institute (USA); University of Oxford
  • Class Amines; Antineoplastics; Isoxazoles; Pyrazines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Gastric cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • No development reported Acute myeloid leukaemia; Head and neck cancer; Oesophageal cancer

Most Recent Events

  • 25 Jan 2024 Efficacy and adverse event data from a phase II trial in Urgenital cancer presented at the Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 11 Oct 2023 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 21 Jul 2023 EMD Serono Research & Development Institute completes phase-II DDRiver SCLC 250 trial in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in Spain, Japan, Italy, France, China, Belgium and USA (IV) (NCT04768296)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top